Tuesday, February 19, 2013 10:42:32 AM
MENLO PARK, CA -- (Marketwire) -- 02/19/13 -- AntriaBio, Inc. (OTCQB: ANTB) is pleased to announce the appointment, on January 31, 2013 , of two new members to its management team: Nevan Elam , as AntriaBio's President and Chief Executive Officer and Sankaram Mantripragada , Ph.D., as AntriaBio's Chief Scientific Officer.
Nevan Elam has spent his entire career starting, managing and advising emerging growth companies in key areas of business including finance, marketing and clinical development. Prior to joining AntriaBio, Mr. Elam served as Chief Executive Officer of AeroSurgical Limited , a medical device company based in Europe . Prior to that, he directed the Pulmonary Business Unit of Nektar Therapeutics, which was sold to Novartis in 2008.
Mr. Elam also serves as a managing director of Konus Advisory Group, Inc. ("Konus"), a boutique healthcare consulting and investment firm that specializes in working with U.S. and European healthcare organizations on business opportunities in Asia , Latin America and the Middle East . Mr. Elam holds a J.D. from Harvard University and Bachelor's degree from Howard University .
Sankaram Mantripragada , Ph.D. brings to AntriaBio his strong understanding of the diabetes market and AntriaBio's unique platform technology. From June 2005 until October 2009 , Dr. Mantripragada served as Vice President of R&D at PR Pharmaceuticals, Inc. ("PRP"). In January 2013 , AntriaBio purchased substantially all of the PRP assets including significant technology, formulation, manufacturing, and intellectual property assets, which together form the basis of AntriaBio's drug development portfolio.
"Dr. Mantripragada's history with PRP's technology and formulation assets and his deep experience in diabetes products and markets make him a clear choice to lead our product development efforts," said Steve Howe , Executive Chairman of AntriaBio. Mr. Howe served as Chairman and Chief Executive Officer of PRP from its formation in 1998 to 2010.
Dr. Mantripragada has been an advisor to companies specializing in diabetes, cell based therapies and cardiovascular diseases. He is listed as an inventor on more than eight patents.
Prior to joining PRP, Dr. Mantripragada served as Director of R&D at Guidant Corporation , now part of Abbott Vascular . Prior to that, he served as Director of R&D and VP of Scientific Development at SkyePharma. Prior to that, he was an Assistant Professor of Biochemistry at the University of Virginia School of Medicine . Dr. Mantripragada obtained his Ph.D. in Molecular Biophysics from the Indian Institute of Science and completed a postdoctoral research program at the Max Planck Institute for Biophysical Chemistry in Germany .
Recent RZLT News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/24/2024 09:14:46 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/19/2024 08:23:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/19/2024 08:09:55 PM
- Rezolute Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 09/19/2024 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/09/2024 11:30:26 AM
- FDA Lifts Partial Clinical Holds on RZ358 for the Treatment of Congenital Hyperinsulinism and Authorizes U.S. Inclusion in Ongoing Phase 3 Study • GlobeNewswire Inc. • 09/09/2024 11:30:00 AM
- Rezolute to Participate in Upcoming Investor Conferences • GlobeNewswire Inc. • 08/27/2024 12:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 08/15/2024 04:15:11 AM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 08/10/2024 01:47:17 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 08/05/2024 09:00:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/05/2024 11:30:33 AM
- Rezolute Announces FDA Clearance of IND Application for Phase 3 Registrational Study of RZ358 for Treatment of Hypoglycemia Due to Tumor Hyperinsulinism • GlobeNewswire Inc. • 08/05/2024 11:30:00 AM
- Rezolute to Participate in the BTIG Virtual Biotechnology Conference • GlobeNewswire Inc. • 07/31/2024 12:00:00 PM
- Rezolute Announces Exercise of Underwriters’ Option to Purchase Additional Shares and Concurrent Private Placement • GlobeNewswire Inc. • 06/27/2024 12:00:00 PM
- Rezolute Announces Closing of Public Offering with Approximately $60M in Gross Proceeds • GlobeNewswire Inc. • 06/24/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/14/2024 08:51:28 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 06/14/2024 08:49:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 04:51:20 PM
- Rezolute Announces Pricing of Public Offering of $60 Million of Common Stock and Pre-Funded Warrants • GlobeNewswire Inc. • 06/14/2024 03:30:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 06/13/2024 09:25:55 PM
- Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants • GlobeNewswire Inc. • 06/13/2024 08:01:00 PM
- Rezolute to Participate in the Jefferies Global Healthcare Conference • GlobeNewswire Inc. • 05/30/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/28/2024 06:56:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/24/2024 06:37:52 PM
- Rezolute Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME) • GlobeNewswire Inc. • 05/21/2024 08:05:00 PM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM